STAT NewsOriginal article
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
Data ReadoutnegativeretatrutideNegative
AI Analysis
Summary
A clinical study of Eli Lilly's retatrutide in patients with heart disease failed to demonstrate whether the weight loss drug reduces cardiovascular risk, a critical endpoint for the obesity indication.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Study did not answer whether retatrutide reduces cardiovascular risk
Importance:6/10
Sentiment:
-0.60
obesityweight losscardiovascularclinical trialGLP-1
Related Companies
Read the original article
Published by STAT News on July 23, 2026 1:21 PM